Cargando…

Chemotherapy-induced polyneuropathy in cancer care—the patient perspective

PURPOSE: Chemotherapy-related polyneuropathy (CIPN) is a very common, often dose-limiting side effect that affects the patients’ quality of life. Treatment usually consists of a combination of medicinal, medical, and individualized treatment approaches, although the effectiveness of these therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Prager, K., Passig, K., Micke, O., Zomorodbakhsch, B., Keinki, C., Hübner, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042917/
https://www.ncbi.nlm.nih.gov/pubmed/36971861
http://dx.doi.org/10.1007/s00520-023-07688-5
_version_ 1784913035597447168
author Prager, K.
Passig, K.
Micke, O.
Zomorodbakhsch, B.
Keinki, C.
Hübner, J.
author_facet Prager, K.
Passig, K.
Micke, O.
Zomorodbakhsch, B.
Keinki, C.
Hübner, J.
author_sort Prager, K.
collection PubMed
description PURPOSE: Chemotherapy-related polyneuropathy (CIPN) is a very common, often dose-limiting side effect that affects the patients’ quality of life. Treatment usually consists of a combination of medicinal, medical, and individualized treatment approaches, although the effectiveness of these therapies is insufficient for many patients. The aim of this article is to review and evaluate the impact of CIPN on patients’ daily lives and possible effective treatment approaches. METHODS: A standardized questionnaire was developed based on ten anonymous telephone interviews with CIPN patients. The content of the questionnaire was divided into 5 categories: demographics, clinical presentation, everyday symptoms, treatment of CIPN symptoms, and medical care. Mostly closed questions were used but multiple choice and individual additions by free text answers were possible. RESULTS: CIPN limits patients’ quality of life over a long period of time. In addition to diurnal and situational fluctuations, the emotional burden negatively affects patients’ daily lives in many ways. From the patients’ point of view, the individually implemented therapy measures were most effective in treating their complaints. But even the combination of different therapy methods insufficiently alleviates the symptoms of the patients. CONCLUSION: It is important and necessary to comprehensively inform patients about CIPN as a possible side effect, to point out prevention strategies, and to critically examine and evaluate different therapy approaches. In this way, misunderstandings of the doctor-patient relationship can be avoided. In addition, patient satisfaction and quality of life can be increased in the long term. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07688-5.
format Online
Article
Text
id pubmed-10042917
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100429172023-03-29 Chemotherapy-induced polyneuropathy in cancer care—the patient perspective Prager, K. Passig, K. Micke, O. Zomorodbakhsch, B. Keinki, C. Hübner, J. Support Care Cancer Research PURPOSE: Chemotherapy-related polyneuropathy (CIPN) is a very common, often dose-limiting side effect that affects the patients’ quality of life. Treatment usually consists of a combination of medicinal, medical, and individualized treatment approaches, although the effectiveness of these therapies is insufficient for many patients. The aim of this article is to review and evaluate the impact of CIPN on patients’ daily lives and possible effective treatment approaches. METHODS: A standardized questionnaire was developed based on ten anonymous telephone interviews with CIPN patients. The content of the questionnaire was divided into 5 categories: demographics, clinical presentation, everyday symptoms, treatment of CIPN symptoms, and medical care. Mostly closed questions were used but multiple choice and individual additions by free text answers were possible. RESULTS: CIPN limits patients’ quality of life over a long period of time. In addition to diurnal and situational fluctuations, the emotional burden negatively affects patients’ daily lives in many ways. From the patients’ point of view, the individually implemented therapy measures were most effective in treating their complaints. But even the combination of different therapy methods insufficiently alleviates the symptoms of the patients. CONCLUSION: It is important and necessary to comprehensively inform patients about CIPN as a possible side effect, to point out prevention strategies, and to critically examine and evaluate different therapy approaches. In this way, misunderstandings of the doctor-patient relationship can be avoided. In addition, patient satisfaction and quality of life can be increased in the long term. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07688-5. Springer Berlin Heidelberg 2023-03-27 2023 /pmc/articles/PMC10042917/ /pubmed/36971861 http://dx.doi.org/10.1007/s00520-023-07688-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Prager, K.
Passig, K.
Micke, O.
Zomorodbakhsch, B.
Keinki, C.
Hübner, J.
Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title_full Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title_fullStr Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title_full_unstemmed Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title_short Chemotherapy-induced polyneuropathy in cancer care—the patient perspective
title_sort chemotherapy-induced polyneuropathy in cancer care—the patient perspective
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042917/
https://www.ncbi.nlm.nih.gov/pubmed/36971861
http://dx.doi.org/10.1007/s00520-023-07688-5
work_keys_str_mv AT pragerk chemotherapyinducedpolyneuropathyincancercarethepatientperspective
AT passigk chemotherapyinducedpolyneuropathyincancercarethepatientperspective
AT mickeo chemotherapyinducedpolyneuropathyincancercarethepatientperspective
AT zomorodbakhschb chemotherapyinducedpolyneuropathyincancercarethepatientperspective
AT keinkic chemotherapyinducedpolyneuropathyincancercarethepatientperspective
AT hubnerj chemotherapyinducedpolyneuropathyincancercarethepatientperspective